HK. JELLIS was an Open Label trial with several limitations ( 65% postmenopausal Japanese women etc ) so was largely ignored by medical authorities in the US and I believe in the EU .
If it had been a double blinded placebo controlled international Outcome trial ...ie an R-IT trial then I assume they could have got a patent for CV risk reduction ....but doubt if they could on JELIS alone .
Just my guess here . Kiwi
PS. do you know the site and how to connect for the oral argument tomorrow ? thx
Market Data 
Markets 
AI
